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Point-of-care HPV molecular diagnostics for a test-and-treat 
model in high-risk HIV populations
Strategies for cervical cancer prevention and control 
in low-income and middle-income countries (LMICs) 
require concerted efforts to improve screening 
and access to treatment, especially in high-risk HIV 
populations. LMICs bear the largest burden of HIV 
infection, human papillomavirus (HPV) infection is 
common among HIV-infected women, risk of cervical 
cancer is increased in women with HIV/AIDS, and HIV 
clinics provide opportunities to screen and treat for 
cervical cancer in this population.
A cluster randomised trial from India has shown that 
one round of HPV screening reduced advanced cervical 
cancer and mortality compared with the standard care 
group, whereas the so-called see and treat method 
(visual inspection of the cervix with acetic acid, VIA) did 
not show such benefit.1 Furthermore, overtreatment and 
undertreatment due to the low sensitivity and specificity 
of the current screening tests are a real problem and they 
reduce the impact of screening in health systems that are 
already overstretched and under-resourced.
Implementation of the traditional Pap smear in national 
screening programmes is not sustainable in under-
resourced LMIC settings with a limited skilled cytologist 
workforce2 and where, despite a high prevalence of 
cervical cancer,3 loss to follow-up and poor adherence 
to treatment are major impediments for programmatic 
success. The current WHO recommendation for HPV 
testing as a primary cervical cancer screening tool has 
been adopted by countries such as Kenya, where it forms 
part of the national cancer screening guidelines.
However, a concern with the HPV screen-and-treat 
approach is the overtreatment of high-risk HPV-
positive women. There is a need for innovative point-
of-care molecular diagnostic tools that are sensitive 
and specific and can be integrated into primary 
health settings in LMICs as screen-and-treat models. 
These point-of-care platforms can further be used to 
diagnose multiple conditions and monitor therapy on 
a single device.4
There are multiple HPV point-of-care testing platforms 
in the market (eg, the careHPV test, Qiagen), but none 
of these has been fully validated in the clinical setting. 
Devices such as the GeneXpert (Cepheid, Sunnyvale, CA, 
USA), which has been endorsed by WHO for molecular 
diagnosis of tuberculosis and rifampicin resistance5 
and which requires minimum training, have created 
opportunities for disease diagnostic testing; GeneXpert 
is currently the only validated HPV point-of-care device. 
The GeneXpert, developed by Cepheid for rapid molecular 
diagnostics,6 combines cartridge-based microfluidic 
sample preparation with RT-PCR-based fluorescent 
signal detection with the capacity to perform RNA 
isolation, reverse transcription, and quantitative PCR in 
about 35 min.8 To date, there are over 7000 GeneXpert 
platforms globally, the majority of which are in low-
income and middle-income countries and are being used 
almost exclusively for tuberculosis diagnosis.7
However, for the point-of-care HPV tests to be 
adopted, they must be widely applicable, specifically in 
high-risk HIV populations. In The Lancet Global Health, 
Louise Kuhn and colleagues8 describe a clinical study 
from South Africa and provide a comprehensive 
background of the current limitation of the GeneXpert 
for screening a high-risk HIV positive population. 
They describe a novel modification of the test that 
would increase the specificity of detecting cervical 
intraepithelial neoplasia of grade 2 (CIN2+) on the 
same device by up to 26% without compromising the 
sensitivity of the test in high-risk HIV-positive women. 
Furthermore, by restricting the channels to the eight 
high-risk HPV genotypes (HPV 16, 18, 45, 31, 33, 35, 
52, and 58), they demonstrate that specificity increased 
by about 4·4% in the HIV-negative population and 
by 17·1% in the HIV-positive population. The positive 
predictive value increased by 2·2–3·6% for CIN2+.
Specificity is important in a screening test to avoid 
overtreatment. New studies9 suggest that loop electro-
surgical excision procedure (LEEP) might be better than 
cryotherapy (ie, lower recurrence of CIN2+ lesions) 
among HIV-infected women, but overtreatment with 
LEEP might have worse consequences than cryotherapy 
given the side-effects associated with LEEP such as 
cervical stenosis and bleeding. A more specific test is 
thus welcome. Kuhn and colleagues also suggest that 
the HPV screen-and-treat method can leverage on the 
VIA or Lugol’s Iodine (VILI) infrastructure already in 
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place in many LMICs—a point that we agree with given 
that minimal training is required to perform the HPV 
test on the GeneXpert platform.
However, it is crucial that any new point-of-care test is 
easy to perform, sensitive, and specific, and that it is not 
vulnerable to user error like VIA, which has performed 
poorly in LMICs (the test is subjective and requires 
regular refresher training  to maintain accuracy). The 
new HPV test modification reported on the Gene Xpert 
by Kuhn and colleagues8 might be able to overcome 
this. But, before LMICs adopt point-of-care technologies 
that can surpass fragile health systems and allow for 
testing in the absence of traditional laboratory settings, 
multiple implementation studies examining cost-
effectiveness, feasibility, and acceptability by health-
care workers and by women of HPV screen-and-treat 
methods are needed. More importantly, it would be 
useful to understand how HPV test specificity might be 
affected by immune status, ART use, and age, as these 
variables might reduce specificity of the test.10
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